Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)

NCT02174159 | Completed Phase 1

• 2 other identifiers: 8507-0032014-000660-18
• Study Type: interventional
• Target: 18
• Locations: 0 countries
• Sites: N/A

Brief Summary

The study will evaluate the safety, tolerability, pharmacokinetics, and antiretroviral activity of a single dose of ulonivirine in antiretroviral therapy (ART)-naive, HIV-1 infected participants. The hypothesis tested in the study is that at a safe and well-tolerated dose, ulonivirine has superior antiretroviral activity to a historical placebo control, as measured by change from baseline in plasma HIV-1 ribonucleic acid (RNA) at 168 hours postdose.

Conditions

HIV-1 Infection

Outcome Measures

Primary Outcomes (2)

• Change from Baseline in Plasma HIV-1 RNA

  168 hours (7 days) postdose

• Number of Participants with One or More Adverse Experiences

  Up to 21 days postdose

Secondary Outcomes (6)

• Area Under the Plasma Concentration-Time Curve of Ulonivirine (AUC0-168hr)

  Up to 168 hours postdose

• Maximum Plasma Concentration of Ulonivirine (Cmax)

  Up to 336 hours postdose

• Time of Maximum Plasma Concentration of Ulonivirine (Tmax)

  Up to 336 hours postdose

• Plasma Concentration of Ulonivirine at 168 Hours Postdose (C168hr)

  168 hours postdose

• Plasma Concentration of Ulonivirine at 336 Hours Postdose (C336hr)

  336 hours postdose

Study Arms (3)

Panel A: Ulonivirine 600 mg

EXPERIMENTAL

Single oral dose of ulonivirine 600 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast

Drug: Ulonivirine

Panel B: Ulonivirine 150 mg

EXPERIMENTAL

Single oral dose of ulonivirine 150 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast

Drug: Ulonivirine

Panel C: Ulonivirine <=600 mg

EXPERIMENTAL

Single oral dose of ulonivirine \<=600 mg mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast. Inclusion of Panel C in the study, and the dose selected, will be decided pending evaluation of results for Panels A and B.

Drug: Ulonivirine

Interventions

Ulonivirine DRUG

MK-8507 administered as a single oral dose

Also known as: MK-8507

Panel A: Ulonivirine 600 mg; Panel B: Ulonivirine 150 mg; Panel C: Ulonivirine <=600 mg

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Male, or non-pregnant and non-breastfeeding female, or postmenopausal or surgically sterile female (confirmed with medical records, examination, or laboratory test). Male participants with female partner of childbearing potential agrees to use a medically acceptable method of contraception during the study and 90 days after receiving study drug.
• Body mass index \<=35 kg/m\^2
• Other than HIV infection, baseline health judged to be stable at screening and/or prior to administration of study drug
• No clinically-significant electrocardiogram abnormality
• Documented to be HIV-1 positive as determined by a positive enzyme-linked immunosorbent assay (ELISA) or quantitative polymerase chain reaction (PCR) result with confirmation
• Has a screening plasma Cluster of Differentiation (CD4) T-cell count of \>200 /mm\^3
• Has a plasma HIV-1 RNA \>= 10,000 copies/mL within 30 days before administration of study drug
• ART-naive, defined as never having received any ART agent, or have received \<=30 consecutive days of an investigational ART agent, excluding non-nucleoside reverse transcriptase inhibitors (NNRTIs), or have received \<=60 consecutive days of combination ART, excluding NNRTIs
• Has not received an investigational agent or licensed ART within 30 days of study drug administration
• Diagnosed with HIV-1 infection \>=3 months before screening
• Willing to receive no other ART for the duration of the study
• Has no evidence of mutations conferring resistance to NNRTIs at screening

You may not qualify if:

• Mentally or legally institutionalized or incapacitated, has significant emotional problems, or has a history of clinically significant psychiatric disorder
• History of clinically significant and not stably controlled abnormalities or diseases
• History of cancer, with the exceptions of 1) adequately-treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix, 2) other malignancies which have been successfully treated \>=10 years before screening, or 3) participants who are highly unlikely to sustain a recurrence for the duration of the study
• History of significant multiple and/or severe allergies, or has had an anaphylactic reaction or significant intolerability to drugs or food
• Positive for hepatitis B surface antigen
• History of chronic hepatitis C virus (HCV) unless there has been a documented cure or a negative HCV viral load
• Had major surgery, or donated or lost \>=1 unit (\~500 mL) of blood within 4 weeks before screening
• Participated in another investigational trial within 4 weeks before administration of study drug
• Unable to refrain from or anticipates the use of any medication beginning 4 weeks before administration of study drug and throughout the trial. Certain medications are permitted.
• Consumes \>3 glasses of alcoholic beverages per day (1 glass is equivalent to 12 ounces of beer, 4 ounces of wine, or 1 ounce of distilled spirits). Participants who consume 4 glasses of alcoholic beverages per day may be enrolled at the discretion of the investigator.
• Consumes \>10 cigarettes per day and is unwilling to restrict smoking to \<=10 cigarettes per day
• Regular user of any illicit drugs or has a history of drug abuse (including alcohol) within 2 years
• Has an immediate family member who is investigational site or sponsor staff directly involved with the trial

Sponsors & Collaborators

• Merck Sharp & Dohme LLC: lead

Related Publications (1)

• Schurmann D, Jackson Rudd D, Schaeffer A, De Lepeleire I, Friedman EJ, Robberechts M, Zhang S, Liu Y, Kandala B, Keicher C, Daumer M, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Ankrom W. Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week. J Acquir Immune Defic Syndr. 2022 Feb 1;89(2):191-198. doi: 10.1097/QAI.0000000000002834.

  PMID: 34654041 RESULT

MeSH Terms

Interventions

ulonivirine

Study Officials

• Medical Director

  Merck Sharp & Dohme LLC

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 24, 2014
• First Posted: June 25, 2014
• Study Start: September 15, 2014
• Primary Completion: July 16, 2015
• Study Completion: July 23, 2015
• Last Updated: April 10, 2023

Record last verified: 2023-04

Data Sharing

• IPD Sharing: Will share